From Consumer App to Enterprise Platform: The Circadify Story

Most health tech companies start with a big idea and a consumer app. Few make the jump to enterprise. Circadify is one of the companies that actually did, and the path from "try scanning your face with your phone" to "here's an SDK that insurance carriers embed in their underwriting workflows" tells you something about where contactless vitals technology is headed in 2026.

"Remote photoplethysmography has moved from lab curiosity to production infrastructure faster than most people in the industry expected. The companies that survived did so by finding buyers with real budgets and real problems." — Dr. Daniel McDuff, formerly of Microsoft Research, whose early work on affective computing and camera-based physiological sensing helped establish rPPG as a viable commercial technology

The consumer starting point

Circadify began where a lot of rPPG companies begin: with a consumer-facing app that lets people measure heart rate, respiratory rate, blood oxygen, and stress through their phone camera. The technology works by capturing subtle color changes in the skin caused by blood flow. A 30-second face scan, decent lighting, and a relatively still subject are all it takes.

The underlying science has been around for a while. Verkruysse, Svaasand, and Nelson published the foundational rPPG paper in Optics Express back in 2008, showing that a standard webcam could detect pulse signals from reflected light on the face. In the years since, researchers like De Haan and Jeanne at Philips Research refined the approach with algorithms like CHROM (2013) and POS (2014), which improved robustness against motion and lighting changes.

By the time consumer rPPG apps hit app stores, the technology worked well enough for casual use. But casual use doesn't build a company. The consumer health app market is brutally competitive, margins are thin, and user retention is low. People download a heart rate app, try it twice, and forget about it.

Why the enterprise pivot happened

The Circadify consumer enterprise platform story follows a pattern that repeats across health tech. Consumer apps generate awareness and prove that the technology works in the real world with real people on real phones. But the revenue model is weak. Subscriptions churn. Ad-supported health apps feel wrong. Freemium only works if the premium tier solves an actual problem, and most consumers don't have a $50-a-month problem with their heart rate.

Enterprise buyers do have expensive problems. Insurance carriers spend $100 to $200 per applicant on paramedical exams. Telehealth platforms run video visits with zero objective health data. Corporate wellness programs fly nurses to office buildings for biometric screening events that cost six figures and take weeks to schedule.

Camera-based vitals solve each of those problems differently, but the underlying engine is the same. That realization is what drives consumer-to-enterprise transitions in rPPG. You don't need a different product for each buyer. You need a different wrapper around the same core technology.

Dimension	Consumer app	Enterprise platform
Revenue model	Subscriptions, freemium	Per-scan API pricing, annual contracts
Integration	Standalone app	SDK embedded in partner platforms
Buyer	Individual user	CTO, VP of underwriting, wellness director
Sales cycle	Instant download	3-12 month evaluation
Retention driver	Personal curiosity	Workflow dependency
Data requirements	Approximate readings	Audit trails, compliance documentation
Scale requirement	Handles one user	Handles thousands of concurrent scans

What the platform actually looks like now

Circadify's current offering measures over 30 health markers through its rPPG engine, including heart rate, heart rate variability, respiratory rate, blood oxygen saturation, blood pressure estimation, and a stress index. The technology runs through a web SDK built in JavaScript/TypeScript for browser-based deployments, and through REST API endpoints that can be consumed from Python, Java, Go, Swift, Kotlin, and other languages.

That flexibility matters. An insurance carrier doesn't want to ship a standalone Circadify app to applicants. They want to embed a 30-second vitals scan inside their existing application portal. A telehealth platform wants the scan to happen during the video visit, inside their own interface. A corporate wellness vendor wants it in their branded employee app.

The SDK approach lets all of those happen without Circadify's name appearing anywhere. White-label deployment means the enterprise partner owns the user experience, and Circadify provides the measurement engine underneath.

Insurance underwriting

The insurance use case is probably the most financially clear. Traditional life insurance underwriting requires an applicant to schedule a paramedical exam, wait for a nurse to visit their home, submit to blood draws and physical measurements, and then wait weeks for lab results. Many applicants just quit before the exam happens. Industry data suggests application abandonment rates in the 20-30% range for exam-required policies.

A camera-based vitals scan takes 30 seconds and can happen on the applicant's phone immediately after they fill out their application. No scheduling, no nurse, no needles, no lab. The data feeds directly into the underwriting decision engine. Whether that data alone is sufficient for final underwriting decisions is still being worked out by carriers and regulators, but as a triage tool to sort applicants into risk tiers and determine who actually needs a full exam, it's already useful.

Telehealth

Before camera-based vitals, a telehealth visit was a video call without vital signs. The doctor could see you but had no heart rate, no respiratory rate, no SpO2. PanopticAI, a Hong Kong-based company, received FDA clearance for contactless pulse rate monitoring through a mobile app, which showed the regulatory pathway exists for this kind of measurement. Integrating rPPG into telehealth platforms means the patient's phone captures vitals data during the visit itself and pipes it into the clinical record.

Automotive

In-cabin driver monitoring is a newer application. Euro NCAP began factoring driver monitoring into its safety ratings starting in 2024, and the 2025 update further increased the scoring weight for systems that detect drowsiness and inattention. Camera-based vitals can go further than eye tracking alone, detecting physiological signs of fatigue or stress by reading the driver's heart rate and heart rate variability through an in-cabin camera. Circadify offers custom-trained rPPG models optimized for specific camera types and lighting conditions, which matters for automotive where IR cameras and variable cabin lighting create a very different signal environment than a phone camera in a well-lit room.

The market is growing faster than most people realize

The photoplethysmography analytics market reached $1.09 billion in 2025 and is expected to hit $1.29 billion in 2026, growing at an 18.7% compound annual growth rate, according to Research and Markets. Persistence Market Research projects the PPG biosensors segment specifically will grow from $700 million in 2026 to $2.2 billion by 2033 at a 16.8% CAGR.

Those numbers cover the broader PPG market, which includes both contact-based and remote (camera-based) photoplethysmography. The remote segment is smaller but growing faster because it eliminates hardware entirely. No sensor, no wearable, no device. Just a camera that's already in every phone, laptop, tablet, and kiosk.

For context, Becker's Hospital Review reported that 16 health tech startups reached unicorn status in 2025 alone. The capital flowing into health technology is real, and contactless vitals sits at an intersection that investors find attractive: AI, cameras, healthcare, and platform economics.

Current research and evidence

The academic foundation for rPPG continues to expand. A 2025 review published in Frontiers in Digital Health, with contributions from researchers associated with IntelliProve, surveyed the state of rPPG-based health assessment and confirmed that the technology supports reliable measurement of heart rate, heart rate variability, respiratory rate, and blood oxygen saturation. The review also noted that blood pressure estimation and stress indicators are measurable but require more validation work, particularly across diverse skin tones and lighting conditions.

McDuff and colleagues at Microsoft Research published extensively on using cameras for affective computing and physiological measurement, and that body of work influenced how commercial systems approach signal extraction and noise filtering. The algorithms running in production today are direct descendants of research that started in university labs less than 15 years ago.

Wang, Den Brinker, and De Haan at Eindhoven University of Technology and Philips Research have continued refining rPPG methods, publishing work on algorithmic robustness that specifically addresses the practical problems of skin tone diversity and motion artifacts. Their research has been cited in hundreds of subsequent papers and directly informs how commercial SDKs handle edge cases.

What comes next for Circadify

The trajectory here follows the classic platform playbook. Start with a single application (consumer vitals scanning), prove the technology works with real users, then package the core engine as infrastructure that other companies build on top of.

Circadify now operates across multiple verticals: insurance underwriting, telehealth, corporate wellness, chronic care management, remote patient monitoring, automotive cabin monitoring, fraud and deepfake detection through liveness verification, and custom deployments for hardware OEMs and IoT device makers. Each of these markets has different buyers, different integration requirements, and different regulatory considerations, but they all run on the same rPPG engine.

The consumer app still exists, and it still matters. It's the top of the funnel, the easiest way for someone to see the technology working on their own face, and a low-friction entry point that often leads to enterprise conversations. Somebody tries the consumer scan, realizes it works, and starts thinking about what it could do inside their company's product.

That loop, from consumer curiosity to enterprise deployment, is the Circadify consumer enterprise platform story in a sentence.

Frequently asked questions

What is Circadify's core technology?

Circadify uses remote photoplethysmography (rPPG) to measure vital signs through a standard phone or device camera. The camera detects tiny color changes in the skin caused by blood flow, and algorithms extract heart rate, respiratory rate, blood oxygen, blood pressure estimates, and other markers from those signals.

How does Circadify's enterprise platform differ from the consumer app?

The enterprise platform provides SDKs and APIs that other companies embed in their own products. Instead of downloading a Circadify-branded app, an insurance carrier or telehealth platform integrates Circadify's measurement engine into their existing workflow. The data, branding, and user experience belong to the enterprise partner.

What industries use Circadify's platform?

Insurance underwriting, telehealth, corporate wellness, remote patient monitoring, chronic care management, automotive driver monitoring, identity verification and liveness detection, and custom hardware integrations for kiosks and IoT devices.

Is the rPPG technology proven?

The underlying science dates back to 2008 and has been validated in hundreds of peer-reviewed publications. Commercial deployment is newer, and the accuracy of specific implementations varies depending on the measurement type, the camera quality, lighting conditions, and the algorithms used. The technology continues to improve as more data becomes available from real-world deployments.

If you want to try Circadify's contactless vitals scan yourself, you can get started at circadify.com.